CelLBxHealth plc Share Price
Stocks
CLBX
GB0034330679
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.275 GBX | 0.00% |
|
+2.00% | +15.91% |
| 07-15 | Beeks in "strong" year; Iofina output up | AN |
| 07-15 | CelLBxHealth plc Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 14.49M 19.33M 16.98M 15.79M 27.22M 1.86B 27.64M 187M 73.25M 915M 72.57M 71.01M 3.16B | P/E 2026 * |
-0.55x | P/E 2027 * | -14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 12.89M 17.2M 15.1M 14.05M 24.22M 1.66B 24.59M 167M 65.16M 814M 64.56M 63.16M 2.82B | EV / Sales 2026 * |
0.6x | EV / Sales 2027 * | 0.42x |
| Free-Float |
94.31% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: CelLBxHealth plc
| 16/10/25 | Angle names Peter Collins as interim CEO | AN |
| 28/05/25 | RBC cuts National Grid; Citigroup cuts South32 | AN |
| 23/01/25 | HSBC raises FirstGroup, Goldman cuts Ithaca | AN |
| 14/09/23 | JPMorgan ups Rio Tinto; Redburn likes Carnival | AN |
| 24/01/22 | Berenberg Initiates Angle With Buy Rating, Sets PT | MT |
| 1 week | +2.00% | ||
| Current month | -16.39% | ||
| 1 month | -16.39% | ||
| 3 months | +30.77% | ||
| 6 months | +6.25% | ||
| Current year | +15.91% |
| 1 week | 1.2 |  | 1.35 |
| 1 month | 1.2 | | 1.67 |
| Current year | 0.85 | | 2.8 |
| 1 year | 0.85 | | 8 |
| 3 years | 0.85 | | 37.4 |
| 5 years | 0.85 | | 163.75 |
| 10 years | 0.85 | | 163.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sinéad Armstrong
DFI | Director of Finance/CFO | - | 31/12/1998 |
| Chief Tech/Sci/R&D Officer | - | 31/12/2024 | |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 04/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Groen
CHM | Chairman | 67 | 21/05/2023 |
Klaas de Boer
BRD | Director/Board Member | 61 | 11/01/2026 |
| Director/Board Member | 61 | 11/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 19/12/25 | Buy | Chief Financial Officer | 2,500,000 | 0.7749% | ||
| 19/12/25 | Buy | Chief Executive Officer | 5,000,000 | 1.5497% | ||
| 19/12/25 | Buy | Chairman | 5,000,000 | 1.5497% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +2.00% | -78.75% | -91.77% | 19.33M | |
| -0.36% | -9.20% | +15.65% | -38.35% | 15.54B | |
| -7.90% | +5.00% | -2.15% | +84.41% | 1.65B | |
| -3.20% | -7.65% | -41.40% | -81.89% | 1.09B | |
| -1.41% | -4.66% | -38.57% | +10.83% | 948M | |
| -3.39% | -5.61% | -45.48% | -55.93% | 609M | |
| -2.46% | -5.34% | -51.05% | -58.53% | 505M | |
| +1.87% | +3.51% | +39.11% | -52.08% | 460M | |
| +1.52% | -3.98% | -57.46% | -61.30% | 365M | |
| +0.72% | -4.89% | -22.14% | -37.78% | 344M | |
| Average | -1.46% | -3.02% | -28.23% | -38.24% | 2.15B | |
| Weighted average by Cap. | -1.16% | -7.28% | +4.28% | -30.71% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 21.65M 28.89M 25.37M 23.59M 40.68M 2.78B 41.31M 280M 109M 1.37B 108M 106M 4.73B | 37.75M 50.37M 44.24M 41.14M 70.93M 4.85B 72.02M 489M 191M 2.38B 189M 185M 8.24B |
| Net income | -8.55M -11.41M -10.02M -9.32M -16.06M -1.1B -16.31M -111M -43.23M -540M -42.82M -41.9M -1.87B | -1.85M -2.47M -2.17M -2.02M -3.48M -238M -3.53M -23.94M -9.35M -117M -9.27M -9.07M -404M |
| Net Debt | -1.6M -2.13M -1.87M -1.74M -3.01M -206M -3.05M -20.71M -8.09M -101M -8.01M -7.84M -349M | 1.4M 1.87M 1.64M 1.53M 2.63M 180M 2.67M 18.12M 7.08M 88.43M 7.01M 6.86M 306M |
Employees
114
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | GBX 1.275 | 0.00% | 1,482,927 |
| 23/07/26 | GBX 1.275 | 0.00% | 563,815 |
| 22/07/26 | GBX 1.275 | 0.00% | 346,152 |
| 21/07/26 | GBX 1.275 | +2.00% | 512,783 |
| 20/07/26 | GBX 1.250 | 0.00% | 384,599 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0128GBP
Average target price
0.0400GBP
Spread / Average Target
+213.73%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CLBX Stock
Select your edition
All financial news and data tailored to specific country editions
